StockData

NextCure, Inc. (NXTC) stock

NXTCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30
$6.88+0.18 (+2.76%)

Close on Nov 18, 2026Market cap $31.52MP/E –Yield 0.00%

NextCure net income

Net income is the profit left for shareholders after every expense, interest and tax.

NextCure's net income for the twelve months ending Jun 30, 2026 was -$42.75M. For fiscal 2025 it was -$55.84M. The highest annual figure on record is -$22.80M in fiscal 2018.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$55.84M–
FY2024Dec 31, 2024-$55.65M–
FY2023Dec 31, 2023-$62.72M–
FY2022Dec 31, 2022-$74.73M–
FY2021Dec 31, 2021-$69.39M–
FY2020Dec 31, 2020-$36.60M–
FY2019Dec 31, 2019-$33.74M–
FY2018Dec 31, 2018-$22.80M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$14.89M–
Q1 FY2026Mar 31, 2026-$9.80M–
Q4 FY2025Dec 31, 2025-$9.44M–
Q3 FY2025Sep 30, 2025-$8.62M–
Q2 FY2025Jun 30, 2025-$26.81M–
Q1 FY2025Mar 31, 2025-$10.98M–
Q4 FY2024Dec 31, 2024-$11.60M–
Q3 FY2024Sep 30, 2024-$11.54M–
Q2 FY2024Jun 30, 2024-$15.40M–
Q1 FY2024Mar 31, 2024-$17.11M–
Q4 FY2023Dec 31, 2023-$14.47M–
Q3 FY2023Sep 30, 2023-$14.30M–
Q2 FY2023Jun 30, 2023-$17.86M–
Q1 FY2023Mar 31, 2023-$16.10M–
Q4 FY2022Dec 31, 2022-$17.30M–
Q3 FY2022Sep 30, 2022-$18.91M–
Q2 FY2022Jun 30, 2022-$17.92M–
Q1 FY2022Mar 31, 2022-$20.60M–
Q4 FY2021Dec 31, 2021-$16.94M–
Q3 FY2021Sep 30, 2021-$17.93M–
Q2 FY2021Jun 30, 2021-$17.99M–
Q1 FY2021Mar 31, 2021-$16.53M-269.9%
Q4 FY2020Dec 31, 2020-$15.46M–
Q3 FY2020Sep 30, 2020-$16.37M–
Q2 FY2020Jun 30, 2020-$14.51M–
Q1 FY2020Mar 31, 2020$9.73M–
Q4 FY2019Dec 31, 2019-$10.93M–
Q3 FY2019Sep 30, 2019-$8.43M–
Q2 FY2019Jun 30, 2019-$8.22M–
Q1 FY2019Mar 31, 2019-$6.16M–
Q4 FY2018Dec 31, 2018-$6.86M–
Q3 FY2018Sep 30, 2018-$5.71M–
Q2 FY2018Jun 30, 2018-$5.23M–
Q1 FY2018Mar 31, 2018-$5.00M–

More NextCure figures

See a number that looks wrong?